33322363|t|Haloperidol Induced Cell Cycle Arrest and Apoptosis in Glioblastoma Cells.
33322363|a|Although several antipsychotic drugs have been shown to possess anticancer activities, haloperidol, a "first-generation" antipsychotic drug, has not been extensively evaluated for potential antineoplastic properties. The aim of this study was to investigate the antitumoral effects of haloperidol in glioblastoma (GBM) U87, U251 and T98 cell lines, and the effects of combined treatment with temozolomide (TMZ) and/or radiotherapy, using 4 Gy of irradiation. The viability and proliferation of the cells were evaluated with trypan blue exclusion assay and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis, using the annexin-propidium iodide (PI), and cell cycle, cluster of differentiation (CD) expression and caspase-8 activation were measured using flow cytometry. Treatment with haloperidol significantly reduced cell viability in U87, U251 and T98 GBM cell lines. Haloperidol induced apoptosis in a dose-dependent manner, inhibited cell migration and produced an alteration in the expression of CD24/CD44. The additional effect of haloperidol, combined with temozolomide and radiation therapy, increased tumor cell death. Haloperidol was observed to induce apoptosis and to increase caspase-8 activation. In conclusion, haloperidol may represent an innovative strategy for the treatment of GBM and further studies are warranted in glioma xenograft models and other malignancies.
33322363	0	11	Haloperidol	Chemical	MESH:D006220
33322363	55	67	Glioblastoma	Disease	MESH:D005909
33322363	162	173	haloperidol	Chemical	MESH:D006220
33322363	360	371	haloperidol	Chemical	MESH:D006220
33322363	375	387	glioblastoma	Disease	MESH:D005909
33322363	389	392	GBM	Disease	MESH:D005909
33322363	394	397	U87	CellLine	CVCL:0022
33322363	399	403	U251	CellLine	CVCL:0021
33322363	408	411	T98	CellLine	CVCL:B368
33322363	467	479	temozolomide	Chemical	MESH:D000077204
33322363	481	484	TMZ	Chemical	MESH:D000077204
33322363	599	610	trypan blue	Chemical	MESH:D014343
33322363	631	691	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide	Chemical	MESH:C022616
33322363	693	696	MTT	Chemical	MESH:C070243
33322363	734	750	propidium iodide	Chemical	MESH:D011419
33322363	820	829	caspase-8	Gene	841
33322363	892	903	haloperidol	Chemical	MESH:D006220
33322363	944	947	U87	CellLine	CVCL:0022
33322363	949	953	U251	CellLine	CVCL:0021
33322363	958	965	T98 GBM	CellLine	CVCL:8926
33322363	978	989	Haloperidol	Chemical	MESH:D006220
33322363	1109	1113	CD24	Gene	100133941
33322363	1114	1118	CD44	Gene	960
33322363	1145	1156	haloperidol	Chemical	MESH:D006220
33322363	1172	1184	temozolomide	Chemical	MESH:D000077204
33322363	1218	1223	tumor	Disease	MESH:D009369
33322363	1236	1247	Haloperidol	Chemical	MESH:D006220
33322363	1297	1306	caspase-8	Gene	841
33322363	1334	1345	haloperidol	Chemical	MESH:D006220
33322363	1404	1407	GBM	Disease	MESH:D005909
33322363	1445	1451	glioma	Disease	MESH:D005910
33322363	1479	1491	malignancies	Disease	MESH:D009369
33322363	Negative_Correlation	MESH:D000077204	MESH:D009369
33322363	Negative_Correlation	MESH:D006220	MESH:D009369
33322363	Positive_Correlation	MESH:D006220	841
33322363	Cotreatment	MESH:D000077204	MESH:D006220
33322363	Negative_Correlation	MESH:D006220	MESH:D005909
33322363	Association	MESH:D006220	960
33322363	Association	MESH:D006220	100133941

